KR101458655B1 - Ｎ-치환된 글리신 유도체: 히드록실라제 억제제 - Google Patents

Ｎ-치환된 글리신 유도체: 히드록실라제 억제제 Download PDF

Info

Publication number
KR101458655B1
KR101458655B1 KR1020097016748A KR20097016748A KR101458655B1 KR 101458655 B1 KR101458655 B1 KR 101458655B1 KR 1020097016748 A KR1020097016748 A KR 1020097016748A KR 20097016748 A KR20097016748 A KR 20097016748A KR 101458655 B1 KR101458655 B1 KR 101458655B1
Authority
KR
South Korea
Prior art keywords
hydroxy
oxo
glycine
dihydro
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097016748A
Other languages
English (en)
Korean (ko)
Other versions
KR20090101376A (ko
Inventor
안토니 엔. 쇼우
케빈 제이. 더피
윌리암 헨리 밀러
안드레아 케이. 마이어스
마이클 엔. 짐머만
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39636631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101458655(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20090101376A publication Critical patent/KR20090101376A/ko
Application granted granted Critical
Publication of KR101458655B1 publication Critical patent/KR101458655B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097016748A 2007-01-12 2008-01-11 Ｎ-치환된 글리신 유도체: 히드록실라제 억제제 Active KR101458655B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88471007P 2007-01-12 2007-01-12
US60/884,710 2007-01-12
PCT/US2008/050833 WO2008089052A2 (en) 2007-01-12 2008-01-11 N-substituted glycine derivatives: hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
KR20090101376A KR20090101376A (ko) 2009-09-25
KR101458655B1 true KR101458655B1 (ko) 2014-11-05

Family

ID=39636631

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097016748A Active KR101458655B1 (ko) 2007-01-12 2008-01-11 Ｎ-치환된 글리신 유도체: 히드록실라제 억제제

Country Status (20)

Country Link
US (2) US7608621B2 (https=)
EP (2) EP2124565B1 (https=)
JP (1) JP5313925B2 (https=)
KR (1) KR101458655B1 (https=)
CN (1) CN101626685B (https=)
AR (1) AR064878A1 (https=)
AU (1) AU2008206441B2 (https=)
BR (1) BRPI0806566A2 (https=)
CA (1) CA2675252C (https=)
CL (1) CL2008000066A1 (https=)
DK (1) DK2124565T3 (https=)
EA (1) EA017112B1 (https=)
ES (2) ES2528745T3 (https=)
HR (1) HRP20150119T1 (https=)
MX (1) MX2009007548A (https=)
PL (1) PL2124565T3 (https=)
PT (1) PT2124565E (https=)
SI (1) SI2124565T1 (https=)
TW (1) TW200845991A (https=)
WO (1) WO2008089052A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI336260B (en) * 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
ITMI20051085A1 (it) * 2005-06-10 2006-12-11 Acs Dobfar Spa Metodo di purificazione del cefotetan
US8450351B2 (en) * 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010025087A1 (en) * 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010055884A1 (ja) * 2008-11-13 2010-05-20 日本農薬株式会社 ピラジン誘導体類の製造方法及びその中間体類
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
KR101665749B1 (ko) * 2009-10-21 2016-10-12 다이이찌 산쿄 가부시키가이샤 5-하이드록시피리미딘-4-카르복사미드 유도체
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
WO2011115687A2 (en) * 2010-03-19 2011-09-22 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (https=) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
TWI583670B (zh) 2012-07-30 2017-05-21 大正製藥股份有限公司 Partially saturated nitrogenous heterocyclic compounds
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
WO2021127273A1 (en) * 2019-12-20 2021-06-24 Gb004, Inc. 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007869A1 (en) 1995-04-07 2001-07-12 Thomas Michael Bare Alpha-substittuted pyridazino quinoline compounds
US20040063709A1 (en) 2002-01-04 2004-04-01 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007869A1 (en) 1995-04-07 2001-07-12 Thomas Michael Bare Alpha-substittuted pyridazino quinoline compounds
US20040063709A1 (en) 2002-01-04 2004-04-01 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia

Also Published As

Publication number Publication date
USRE44613E1 (en) 2013-11-26
ES2614355T3 (es) 2017-05-30
US20080214549A1 (en) 2008-09-04
AU2008206441A1 (en) 2008-07-24
CN101626685A (zh) 2010-01-13
JP2010515756A (ja) 2010-05-13
SI2124565T1 (sl) 2015-04-30
US7608621B2 (en) 2009-10-27
EP2124565B1 (en) 2015-01-07
PT2124565E (pt) 2015-03-26
AR064878A1 (es) 2009-04-29
BRPI0806566A2 (pt) 2014-05-06
EP2889289A1 (en) 2015-07-01
CL2008000066A1 (es) 2008-08-01
WO2008089052A2 (en) 2008-07-24
EA200970680A1 (ru) 2010-02-26
EP2889289B1 (en) 2016-12-21
KR20090101376A (ko) 2009-09-25
HRP20150119T1 (hr) 2015-05-08
EA017112B1 (ru) 2012-09-28
EP2124565A2 (en) 2009-12-02
MX2009007548A (es) 2009-07-22
EP2124565A4 (en) 2011-06-29
JP5313925B2 (ja) 2013-10-09
CN101626685B (zh) 2013-03-13
CA2675252C (en) 2015-05-26
DK2124565T3 (en) 2015-02-09
PL2124565T3 (pl) 2015-05-29
ES2528745T3 (es) 2015-02-12
TW200845991A (en) 2008-12-01
AU2008206441B2 (en) 2014-06-19
CA2675252A1 (en) 2008-07-24
WO2008089052A3 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
KR101458655B1 (ko) Ｎ-치환된 글리신 유도체: 히드록실라제 억제제
KR101411816B1 (ko) 프롤릴 히드록실라제 억제제
KR102394518B1 (ko) 브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
US20080171756A1 (en) N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors
US20110039895A1 (en) Prolyl hydroxylase inhibitors
US20100305133A1 (en) Prolyl Hydroxylase Inhibitors
US20110144167A1 (en) Prolyl Hydroxylase Inhibitors
WO2009039323A1 (en) Prolyl hydroxylase inhibitors
WO2007038571A2 (en) Prolyl hydroxylase antagonists
WO2009049112A1 (en) Prolyl hydroxylase inhibitors
EP1991227A2 (en) Prolyl hydroxylase inhibitors
WO2007136990A2 (en) Prolyl hydroxylase inhibitors
US20110160227A1 (en) Prolyl Hydroxylase Inhibitors
AU2008329746A1 (en) Prolyl hydroxylase inhibitors
WO2009039321A1 (en) Prolyl hydroxylase inhibitors
WO2009039322A1 (en) Prolyl hydroxylase inhibitors
WO2010059555A1 (en) Prolyl hydroxylase inhibitors
AU2012258439A1 (en) Prolyl hydroxylase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090811

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130110

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140128

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140728

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141030

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141029

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20210927

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20210927

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20220922

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20220922

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee